vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and J.Jill, Inc. (JILL). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $150.5M, roughly 1.1× J.Jill, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -0.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
J.Jill is an American womenswear retailer founded in 1955 in Massachusetts. It has been a publicly traded company since 2017. J.Jill is headquartered in Quincy, Massachusetts.
ESPR vs JILL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $150.5M |
| Net Profit | — | $9.2M |
| Gross Margin | — | 70.9% |
| Operating Margin | 50.6% | 9.9% |
| Net Margin | — | 6.1% |
| Revenue YoY | 143.7% | -0.5% |
| Net Profit YoY | — | -25.5% |
| EPS (diluted) | $0.32 | $0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $150.5M | ||
| Q3 25 | $87.3M | $154.0M | ||
| Q2 25 | $82.4M | $153.6M | ||
| Q1 25 | $65.0M | $142.8M | ||
| Q4 24 | $69.1M | $151.3M | ||
| Q3 24 | $51.6M | $155.2M | ||
| Q2 24 | $73.8M | $161.5M | ||
| Q1 24 | $137.7M | $150.3M |
| Q4 25 | — | $9.2M | ||
| Q3 25 | $-31.3M | $10.5M | ||
| Q2 25 | $-12.7M | $11.7M | ||
| Q1 25 | $-40.5M | $2.2M | ||
| Q4 24 | — | $12.3M | ||
| Q3 24 | $-29.5M | $8.2M | ||
| Q2 24 | $-61.9M | $16.7M | ||
| Q1 24 | $61.0M | $4.8M |
| Q4 25 | — | 70.9% | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | 71.8% | ||
| Q1 25 | — | 66.3% | ||
| Q4 24 | — | 71.4% | ||
| Q3 24 | — | 70.5% | ||
| Q2 24 | — | 72.9% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | 50.6% | 9.9% | ||
| Q3 25 | -11.4% | 10.9% | ||
| Q2 25 | 8.6% | 12.4% | ||
| Q1 25 | -34.0% | 3.6% | ||
| Q4 24 | -6.4% | 12.7% | ||
| Q3 24 | -31.0% | 14.8% | ||
| Q2 24 | 3.5% | 17.6% | ||
| Q1 24 | 52.5% | 7.0% |
| Q4 25 | — | 6.1% | ||
| Q3 25 | -35.9% | 6.8% | ||
| Q2 25 | -15.4% | 7.6% | ||
| Q1 25 | -62.2% | 1.6% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | -57.2% | 5.3% | ||
| Q2 24 | -83.9% | 10.3% | ||
| Q1 24 | 44.3% | 3.2% |
| Q4 25 | $0.32 | $0.60 | ||
| Q3 25 | $-0.16 | $0.69 | ||
| Q2 25 | $-0.06 | $0.76 | ||
| Q1 25 | $-0.21 | $0.11 | ||
| Q4 24 | $-0.14 | $0.80 | ||
| Q3 24 | $-0.15 | $0.54 | ||
| Q2 24 | $-0.33 | $1.16 | ||
| Q1 24 | $0.34 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $58.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $129.0M |
| Total Assets | $465.9M | $458.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $58.0M | ||
| Q3 25 | $92.4M | $45.5M | ||
| Q2 25 | $86.1M | $31.2M | ||
| Q1 25 | $114.6M | $35.4M | ||
| Q4 24 | $144.8M | $38.8M | ||
| Q3 24 | $144.7M | $28.5M | ||
| Q2 24 | $189.3M | $77.1M | ||
| Q1 24 | $226.6M | $62.2M |
| Q4 25 | $-302.0M | $129.0M | ||
| Q3 25 | $-451.4M | $121.5M | ||
| Q2 25 | $-433.5M | $112.0M | ||
| Q1 25 | $-426.2M | $105.8M | ||
| Q4 24 | $-388.7M | $103.3M | ||
| Q3 24 | $-370.2M | $90.4M | ||
| Q2 24 | $-344.2M | $53.1M | ||
| Q1 24 | $-294.3M | $37.2M |
| Q4 25 | $465.9M | $458.0M | ||
| Q3 25 | $364.0M | $436.5M | ||
| Q2 25 | $347.1M | $432.9M | ||
| Q1 25 | $324.0M | $417.7M | ||
| Q4 24 | $343.8M | $418.3M | ||
| Q3 24 | $314.1M | $390.8M | ||
| Q2 24 | $352.3M | $443.9M | ||
| Q1 24 | $373.1M | $428.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $19.1M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 10.6% |
| Capex IntensityCapex / Revenue | 0.0% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.07× |
| TTM Free Cash FlowTrailing 4 quarters | — | $37.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $19.1M | ||
| Q3 25 | $-4.3M | $19.4M | ||
| Q2 25 | $-31.4M | $5.3M | ||
| Q1 25 | $-22.6M | $8.1M | ||
| Q4 24 | $-35.0M | $19.1M | ||
| Q3 24 | $-35.3M | $16.4M | ||
| Q2 24 | $-7.2M | $21.5M | ||
| Q1 24 | $53.8M | $6.6M |
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $17.1M | ||
| Q2 25 | — | $3.1M | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | — | $14.6M | ||
| Q3 24 | $-35.5M | $15.0M | ||
| Q2 24 | $-7.3M | $19.8M | ||
| Q1 24 | $53.8M | $1.8M |
| Q4 25 | — | 10.6% | ||
| Q3 25 | — | 11.1% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | -68.7% | 9.6% | ||
| Q2 24 | -9.9% | 12.2% | ||
| Q1 24 | 39.0% | 1.2% |
| Q4 25 | 0.0% | 2.0% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 4.7% | ||
| Q4 24 | 0.0% | 2.9% | ||
| Q3 24 | 0.3% | 0.9% | ||
| Q2 24 | 0.1% | 1.1% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 1.84× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 3.60× | ||
| Q4 24 | — | 1.54× | ||
| Q3 24 | — | 2.00× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | 0.88× | 1.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
JILL
| Sales Channel Through Intermediary | $80.1M | 53% |
| Sales Channel Directly To Consumer | $70.5M | 47% |
